M2S

Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.

Optasia Medical aims to build medical imaging-based Computer Assisted Detection (CAD) solutions to help physicians make better decisions. With Optasia Medical's tools, medical images can be evaluated more rapidly, more accurately and more reproducibly. The Optasia platform aims to enable robust model-based vision solutions to automated medical image interpretation problems. With Optasia, new applications can be developed rapidly for seamless integration into the clinical workflow.nOptasia Medical is applying the Optasia platform to problems in musculoskeletal disease. Specifically, for the analysis of X-ray images in the detection and monitoring of osteoporosis, osteoarthritis and rheumatoid arthritis and the planning and assessment of orthopedic surgery

NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

Binx Health is a healthcare company focused on point-of-care molecular diagnostics. The company offers diagnostic solutions that enable healthcare providers to deliver timely, high-quality care, including a testing platform for the diagnosis and treatment of chlamydia and gonorrhea infections. Binx Health primarily serves the healthcare industry. Binx Health was formerly known as Atlas Genetics. It was founded in 2005 and is based in Cambridge, Massachusetts.

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

Tympany is developing automated, hearing, diagnostic technology. Tympany aims to improve early detection of hearing loss, increase access to diagnostics, and facilitate the ease and convenience of personalized treatment. The company is located in The Woodlands, Texas, with regional offices throughout the U.S